Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.67)
# 808
Out of 5,112 analysts
108
Total ratings
52.31%
Success rate
7.73%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $216 → $230 | $164.81 | +39.55% | 1 | Dec 16, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Overweight | $4 | $1.70 | +135.29% | 1 | Dec 11, 2025 | |
| VNDA Vanda Pharmaceuticals | Maintains: Overweight | $13 → $11 | $6.65 | +65.41% | 2 | Oct 30, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Overweight | $6 | $3.95 | +52.09% | 1 | Sep 22, 2025 | |
| GOSS Gossamer Bio | Reiterates: Overweight | n/a | $3.47 | - | 1 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $501.27 | +4.73% | 2 | Sep 10, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $51.66 | +74.22% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $447.05 | +7.37% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $53.37 | +3.05% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $121.68 | -34.25% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $9.13 | - | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $1,015 | $742.39 | +36.72% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $323.29 | +25.27% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $396.48 | -44.51% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $16.02 | -37.58% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $5.90 | +10.17% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $55.27 | +30.27% | 1 | Apr 13, 2023 |
Insmed
Dec 16, 2025
Maintains: Overweight
Price Target: $216 → $230
Current: $164.81
Upside: +39.55%
Inhibikase Therapeutics
Dec 11, 2025
Initiates: Overweight
Price Target: $4
Current: $1.70
Upside: +135.29%
Vanda Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $6.65
Upside: +65.41%
CytomX Therapeutics
Sep 22, 2025
Initiates: Overweight
Price Target: $6
Current: $3.95
Upside: +52.09%
Gossamer Bio
Sep 11, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.47
Upside: -
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $501.27
Upside: +4.73%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $51.66
Upside: +74.22%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $447.05
Upside: +7.37%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $53.37
Upside: +3.05%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $121.68
Upside: -34.25%
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $9.13
Upside: -
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $742.39
Upside: +36.72%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $323.29
Upside: +25.27%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $396.48
Upside: -44.51%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $16.02
Upside: -37.58%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $5.90
Upside: +10.17%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $55.27
Upside: +30.27%